Biologics for the treatment of Juvenile Idiopathic Arthritis

Dimitri Poddighe, Micol Romano, Maurizio Gattinara, Valeria Gerloni

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases in children. Recently, the management of JIA has substantially changed, thanks to the availability of new treatment options, represented by biological drugs or biologics. These drugs modulate specific mechanisms of the immune systems, such as TNF-α, IL-1 and IL-6 signaling, or lymphocyte activation and/or functioning. In this review, we provide a comprehensive discussion on the current recommendations and clinical evidences regarding the use of the available biologics in the treatment of JIA; moreover, the main pharmacokinetic and pharmacodynamic aspects of any specific biologic drug have been summarized.

Original languageEnglish
JournalCurrent Medicinal Chemistry
Publication statusE-pub ahead of print - May 21 2018

Fingerprint Dive into the research topics of 'Biologics for the treatment of Juvenile Idiopathic Arthritis'. Together they form a unique fingerprint.

Cite this